Drug Profile
CTX 712
Alternative Names: CTX-712Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Takeda
- Developer Chordia Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Clk dual-specificity kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2023 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT05732103)
- 25 Apr 2023 Phase-I/II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO) (NCT05732103)
- 16 Feb 2023 Chordia Therapeutics and Theradex plans a phase I/II trial for Myelodysplastic syndromes and Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO, Tablet) (NCT05732103)